IRVINE, Calif.–(BUSINESS WIRE)–Irvine, California-based Biogennix, an osteobiologic company which develops, manufactures, and distributes proprietary bone graft substitutes used for bone fusion procedures, announced today that its products have now been used in more than 6000 patients.
The company’s novel bone graft substitutes, osteoSPAN™ and Morpheus™ are resorbable, osteoconductive scaffolds ideally suited for bone regeneration and optimal handling by surgeons. Biogennix’s composites of calcium phosphate and calcium carbonate have complete interconnected porosity and the optimal pore diameter for bone reconstruction. Available in strips, granules and moldable putty, the products are indicated for orthopedic applications including the posterolateral spine, long bone and pelvis.
“We’re proud that our osteoSPAN and Morpheus bone graft products have been so well received by the clinician and patient communities and that we’ve been able to contribute to such positive post-op outcomes for more than 6000 spine surgery patients,” said Dr. Edwin Shors, President of Biogennix. “It’s come to the point where we receive positive feedback from surgeons on a regular basis. We firmly believe that our products are fast becoming the new standard of effectiveness and ease of use when it comes to bone graft substitutes.”
The osteoSPAN bone graft substitute is available in either granular form (1-4mm) or in blocks, called “Fusion Kits.” The granules and blocks serve as bone graft substitutes and they are mixable with autograft for use as a bone graft extender in the posterolateral spine. Handling characteristics favored by surgeons include the product’s compressive strength, wettability, and easy integration with autogenous bone.
Morpheus is a moldable variation of the original osteoSPAN product. The 1-2mm osteoSPAN granules are combined with an organic binder which provides improved intraoperative handling and is packaged in a syringe-like dispenser to facilitate placement and containment of the implant. The binder dissolves quickly, and does not interfere with the osteoconductive properties of the granules. The granules are gradually resorbed and remodeled by bone over the next 6-12 months.
Biogennix is a market leader in advanced bone regeneration technologies. Biogennix is headquartered in Irvine, CA where they develop, manufacture, and distribute proprietary technologies used in bone fusion procedures. Biogennix team members are experts in bone graft science who are focused on creating solutions that keep distributors and surgeons on the forefront of bone regeneration. Learn more about us here.